403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
RNA Therapeutics And Vaccines Market To Soar USD 107.7 Billion By 2034 At Explosive 87% CAGR, Driven By Breakthrough RNA Technologies
(MENAFN- GlobeNewsWire - Nasdaq) The global RNA therapeutics and vaccines market size was valued at USD 0.21 billion in 2024 and is predicted to hit around USD 107.7 billion by 2034, rising at a 87% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.
![]()
Ottawa, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The global RNA therapeutics and vaccines market size
The RNA therapeutics and vaccines market is rising because rapid advances in RNA technology, especially mRNA and self-amplifying RNA platforms are enabling faster, more flexible development of vaccines and therapies for infectious, genetic, and rare diseases, driving unprecedented demand from industry, investors and global health-care systems.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @Key Takeaways:
- RNA therapeutics and vaccines market to crossed USD 0.21 billion by 2024. Market projected at USD 107.7 billion by 2034. CAGR of 87% expected in between 2025 to 2034. By region, North America was dominant in the RNA therapeutics and vaccines market, with approximately 42% share. By region, Asia Pacific is the fastest-growing over the forecast period, 2025 to 2034. By modality type, the mRNA vaccines & therapeutics segment was dominant in the market revenue in 2024, with approximately 38% share. By modality type, the self-amplifying RNA (saRNA) & replicons segment is expected to be the fastest-growing over the forecast period, 2025 to 2034. By therapeutic area/indication, the infectious diseases & vaccines segment dominated the RNA therapeutics and vaccines market revenue in 2024, with approximately 36% share. By therapeutic area/indication, the rare and genetic diseases segment is expected to be the fastest-growing over the forecast period, 2025 to 2034. By product/offering type, the finished drug products segment was dominant in the market in 2024, with approximately 40% share. By product/offering type, the CDMO & contract development services segment is expected to register the fastest growth over the forecast period, 2025 to 2034. By delivery and enabling technology, the lipid nanoparticles (LNPs) & ionizable lipids segment was dominant in the market in 2024, with approximately 34% share. By delivery and enabling technology, the novel lipid chemistries segment is expected to register the fastest growth over the forecast period, 2025 to 2034. By end user, the large pharmaceutical & biotechnology companies segment was dominant in the RNA therapeutics and vaccines market in 2024, with approximately 45% share. By end user, the CDMOs/contract manufacturers segment is expected to register the fastest growth over the forecast period, 2025 to 2034.
Market Overview:
What are the Reasons for the Demand for RNA-Based Therapies?
Many recent studies indicate an extraordinary surge in the international market for RNA-based therapies (including both mRNA and therapeutic products derived from RNA delivery systems) due to an increased need for innovative therapies to treat infectious diseases, genetic-related disorders (including cancers), and especially rare diseases.
With multiple innovations in the use of modularity, scalability, speed, and regulatory acceptability associated with RNA-based platforms (including vaccines and other applications of RNA for therapeutic purposes), there has been an even greater increase in the amount of funding available for research and development related to these platforms and, therefore, an even greater demand for RNA-based therapy products.
By 2024, the RNA-based vaccine and therapeutic industry will shift from a "niche-oriented research phase" to a generalised, widespread application. This trend is corroborated by several displayed elements of the pharmaceutical industry You can place an order or ask any questions, please feel free to contact us at ...Major Growth Drivers:
- The versatility of RNA technology can rapidly develop vaccines and therapeutics for many diseases ranging from Infectious Diseases to Cancer. Therefore, many researchers are taking advantage of RNA-based platforms to create treatment options for druggable targets that were previously treated with standard therapies. Recent advances in delivery systems (specifically related to Lipid Nanoparticle formulations and Lipid Chemistry) and advances in Modular Manufacturing Processes have allowed for significant molecular reduction costs, faster production time and greater stability of all RNA-based therapeutic products. Therefore, it establishes a more accessible pathway to mass manufacture RNA-based therapies. Increasing Public & Private Sector Investment options to develop RNA Product options, as well as the growing trend to Outsource to CDMOs, have enabled the market for RNA-based products to accelerate with greater speed. In addition, with CDMOs capabilities moving products from laboratory to market, the Pharmaceutical Industry is becoming accustomed to developing all types of RNA Products under the same highly efficient model. RNA-based therapies are particularly aligned with the general paradigm of Personalized or Precision Medications including Custom Therapies for specific Genetic or Rare Disorders, therefore representing the highest demand Investment Opportunities in the Biotech Industry
Key Drifts:
Extending beyond infectious diseases into oncology
Significant Challenge:
While the potential for RNA based therapeutics is great, there are still significant barriers that need to be overcome in order for RNA products to be commercialised. These include instability of RNA products, delivery to cells, a cold-chain storage requirement and a complex regulatory pathway. These factors hinder development and increase the total cost of production. In addition, the barriers will further complicate the ability to produce and distribute RNA products globally, especially in lower and middle-income countries that lack distribution infrastructure.
Become a valued research partner with us -Regional Analysis:
North America remains the largest region for RNA therapeutics and vaccines market due to its successful R&D infrastructure, strong investments from both the public and private sectors, and a well-established biopharmaceutical industry biopharmaceutical companies and CDMO's The Asia Pacific region is emerging as the fastest growing region for RNA therapeutics and vaccines market ability to manufacture protein therapeuticsSegmental Insights:
By Type of Modality:
For the mRNA vaccines and therapeutics segment, it has the biggest share of the market in 2024 at 38%. The reason for the 38% share is due to the strong clinical validation of the non-replicating mRNA technologies, which are scalable, safe, and adaptable to accelerate vaccine development. Pharmaceutical companies are increasingly utilising traditional mRNA technologies for vaccines against infectious diseases, oncology candidates and new potential personalised therapies. In addition, continuing improvements in mRNA stabilisation and cold-chain optimisation as well as LNP delivery systems have aided in the commercial adoption of mRNA by regulatory authorities.
Self-amplifying RNA (saRNA) and Replicons will record the fastest growth (2025–2034). The projected growth is attributed to the ability of these platforms to produce a much larger amount of protein at a drastically reduced dose than that of conventional mRNA platforms. This next generation of RNA has the potential for a more robust immune response, reduced costs associated with the production of each dose and to allow for large-scale vaccination efforts in resource-limited countries.
By Therapeutic Area / Indication
Infectious disease and vaccine is projected to be the leading segment for market revenue generation in 2024, accounting for about 36% of total market revenue, due to the ongoing global demand for vaccines, expansion of immunisation initiatives and increased preparedness for the emergence of numerous viral threats. The use of mRNA platforms is also being utilised for vaccines for various viral respiratory diseases, such as seasonal flu, RSV and COVID-19 variants, as well as progressing RNA-based vaccine initiatives against HIV, Zika and malaria. The commercialisation of these vaccines has been increased due to the provision of government support through funding and creation of public/private partnerships and the use of accelerated regulatory pathways to bring mRNA vaccines to market.
This is expected to be the fastest growing segment of the market from 2025 to 2034, therefore is projected to be driven by an increasing interest in precision medicine ability to correct gene expression Get the latest insights on life science industry segmentation with our Annual Membership:By Product/Offering type:
The finished drug products led the market with the largest share in 2024. Finished Drug Products will continue to be the most widely used product types within the market and will have broad-based demand as the market begins to develop several different types of“ready-to-use” RNA vaccines, therapies, and combined products, as well as allow for larger-scale production of finished drug products via the use of pre-filled syringes and vials for the RNA injection market.
The highest market growth rate between 2025 and 2034 is projected to occur for the Contract Development and Manufacturing Organization (CDMO) and Contract Development Services Market. As the amount of data and documentation related to RNA development, synthesis, formulation, analytics, and production continues to increase, CDMO's are likely to provide the greatest amount of growth for this segment because they have become the preferred method used by most biotechnology companies when developing RNA-based therapeutic candidates. CDMO's allow biopharmaceutical companies to avoid spending capital-intensive upfront investments into building and operating dedicated RNA production facilities.
By delivery and enabling technologies:
The leading segment in the market is projected to be the LNP & Ionizable lipid segments, with a predicted market share of 34% in 2024. Most of the growth within RNA Therapeutics Delivery will continue to be supported by the proven safety and stability, along with the relative delivery efficiencies of LNPs and Ionizable Lipids as effective delivery vehicles for delivering both mRNA-based and RNA products. As a result of LNP's proven effectiveness as delivery systems for mRNA-based Therapeutics, LNP-based products remain the standard for delivering mRNA-based therapeutic candidates, as LNP's protect the RNA from the environment and have a high ability to specifically target and release the RNA to the target cells.
Novel lipid chemistry, or new lipid chemistries are projected to have the fastest growth of any segment in the RNA Therapeutics Technology segment, as RNA Developers are focused on developing the next generation of RNA Delivery Technologies. Several categories of innovation exist within this segment; Biodegradable Lipids, New Ionizable Lipid Alternatives, Targeted Lipids, and Customizable Nanoparticle Architectures for Organ-Specific versus Systemic Delivery. The ultimate goal of developing Novel Lipid Chemistries is to address the three major limitations of current RNA Therapeutic Candidates; Toxicity, Tolerance of Repeated Doses, and Delivery Accuracy.
By End Users:
Large pharmaceutical and biopharmaceutical companies represented the largest share 45% of the industry during 2024; their strong financial ability, comprehensive research and development pipelines, and advanced understanding of regulatory processes allow them to create and market RNA therapies quickly. The size of these firms also permits the establishment of a wide network of supply chain partners and, in some cases, to manage "end-to-end" capabilities of the business model (from the time they produce their product until it is available for sale).
Between 2025 and 2034, the segment referred to as contract manufacturing organizations (CMOs) and contract development manufacturing organizations (CDMOs) are expected to grow rapidly as biopharmaceutical companies continue to transfer production of their RNA-based products to CDMO and CMO partners. The services offered by CDMO/CMOs include: (i) advanced capabilities such as high-throughput RNA synthesis, sterile fill-finish services and the ability to produce scalable liposomal nanoparticle formulations, together with (ii) a commitment to producing products under GMP conditions.
Browse More Insights of Towards Healthcare:
The global RNA analysis market size
The RNAi therapeutics market
The global NGS-based RNA-sequencing market
The global liquid biopsy tube market
The consumption-type vaccine market
The injection flu shot market size
The global miRNA sequencing and assay market
The global mRNA quality monitoring market
The global microRNA market
The global gRNA market
Recent Developments:
On November 19, 2025, Moderna announced a US$ 140 million investment to complete its full end-to-end mRNA manufacturing capabilities in the United States, enabling on-site fill-finish drug product production and reducing dependency on external contract manufacturers.
RNA Therapeutics and Vaccines Market Key Players List:
- Moderna, Inc. BioNTech SE Pfizer Inc. Sanofi (including Translate Bio) CureVac N.V. Alnylam Pharmaceuticals, Inc. Ionis Pharmaceuticals, Inc. Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. Beam Therapeutics Inc. Intellia Therapeutics, Inc. Editas Medicine, Inc. Lonza Group Ltd. Catalent, Inc. Acuitas Therapeutics, Inc. Precision NanoSystems, Inc. Thermo Fisher Scientific, Inc. Merck KGaA (MilliporeSigma) Arcturus Therapeutics Holdings Inc. Gritstone Bio, Inc.
Segments Covered in the Report
By Modality / Product Type
- mRNA Vaccines & Therapeutics Small Interfering RNA (siRNA) Therapeutics Antisense Oligonucleotides (ASOs) Self-Amplifying RNA (saRNA) & Replicons RNA Aptamers & Other RNA Modalities RNA-Delivered Gene-Editing Components Delivery Systems & LNP Components
By Therapeutic Area / Indication
- Infectious Diseases & Vaccines Oncology Rare & Genetic Diseases Cardiometabolic & Liver Diseases Neurological Disorders Other
By Product / Offering Type
- Finished Drug Products Drug Substance & Formulation Oligonucleotide API / GMP Synthesis CDMO & Contract Development Services Research Reagents & Preclinical Kits Analytical & QC Testing Services
By Delivery & Enabling Technology
- Lipid Nanoparticles (LNPs) & Ionizable Lipids Non-LNP Carriers Conjugates Novel Lipid Chemistries Formulation & Lyophilization Technologies Delivery Devices Analytical & Characterization Platforms
By End User
- Large Pharmaceutical & Biotechnology Companies CDMOs / Contract Manufacturers Academic & Research Institutions Government & Public Health Agencies Specialty Clinics / Hospitals Diagnostics & Companion Test Developers
By Region
- North America Europe Asia Pacific Latin America Middle East & Africa
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard:About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research You can place an order or ask any questions, please feel free to contact us at ...Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web:Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment